Michael A. Harding

2.2k total citations
30 papers, 2.0k citations indexed

About

Michael A. Harding is a scholar working on Molecular Biology, Cancer Research and Genetics. According to data from OpenAlex, Michael A. Harding has authored 30 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 10 papers in Cancer Research and 5 papers in Genetics. Recurrent topics in Michael A. Harding's work include Cancer, Hypoxia, and Metabolism (4 papers), Bladder and Urothelial Cancer Treatments (4 papers) and Cancer, Lipids, and Metabolism (4 papers). Michael A. Harding is often cited by papers focused on Cancer, Hypoxia, and Metabolism (4 papers), Bladder and Urothelial Cancer Treatments (4 papers) and Cancer, Lipids, and Metabolism (4 papers). Michael A. Harding collaborates with scholars based in United States, Netherlands and Germany. Michael A. Harding's co-authors include Dan Theodorescu, John J Gildea, James P. Calvet, Vincent H. Gattone, Henry F. Frierson, Glen K. Andrews, Eileen D. Adamson, M. Jabed Seraj, Mark R. Conaway and Garret M. Hampton and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael A. Harding

30 papers receiving 1.9k citations

Peers

Countries citing papers authored by Michael A. Harding

Since Specialization

Citations

This map shows the geographic impact of Michael A. Harding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Harding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Harding more than expected).

Fields of papers citing papers by Michael A. Harding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Harding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Harding. The network helps show where Michael A. Harding may publish in the future.

Co-authorship network of co-authors of Michael A. Harding

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Harding. A scholar is included among the top collaborators of Michael A. Harding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Harding. Michael A. Harding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of the DASH diet on the sodium-chloride cotransporter and aquaporin-2 in urinary extracellular vesicles 2024 ·American Journal of Physiology-Renal Physiology ·Dana Bielopolski, Luca Musante, Ewout J. Hoorn, Henrik Molina, Douglas Barrows, (unknown), Michael A. Harding, (unknown), (unknown), (unknown), Jonathan N. Tobin, Rhonda G. Kost, Uta Erdbrügger	2
2	Uromodulin and the study of urinary extracellular vesicles 2024 ·SHILAP Revista de lepidopterología ·Michael A. Harding, (unknown), (unknown), (unknown), Agnieszka Swiatecka‐Urban, Uta Erdbrügger	2
3	CD24 Is an Effector of HIF-1–Driven Primary Tumor Growth and Metastasis 2012 ·Cancer Research ·Shibu Thomas, Michael A. Harding, Steven C. Smith, Jonathan B. Overdevest, Matthew D. Nitz, Henry F. Frierson, Scott A. Tomlins, Glen Kristiansen, Dan Theodorescu	117
4	RREB1 Transcription Factor Splice Variants in Urologic Cancer 2011 ·American Journal Of Pathology ·Matthew D. Nitz, Michael A. Harding, Steven C. Smith, Shibu Thomas, Dan Theodorescu	17
5	RhoGDI signaling provides targets for cancer therapy 2010 ·European Journal of Cancer ·Michael A. Harding, Dan Theodorescu	75
6	The Penetratin Sequence in the Anticancer PNC-28 Peptide Causes Tumor Cell Necrosis Rather Than Apoptosis of Human Pancreatic Cancer Cells 2008 ·Annals of Surgical Oncology ·Wilbur B. Bowne, (unknown), (unknown), Victor Adler, (unknown), (unknown), (unknown), (unknown), M. Kamran Ikram, Michael A. Harding, Martin H. Bluth, (unknown), Paul W. Brandt‐Rauf, (unknown), (unknown), Michael E. Zenilman, Josef Michl, Matthew R. Pincus	13
7	Invasion and Metastasis Models for Studying RhoGDI2 in Bladder Cancer 2008 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Matthew D. Nitz, Michael A. Harding, Dan Theodorescu	16
8	RhoGDI2: A new metastasis suppressor gene: Discovery and clinical translation 2007 ·Urologic Oncology Seminars and Original Investigations ·Michael A. Harding, Dan Theodorescu	35
9	PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity 2004 ·Oncogene ·John J Gildea, Mikael Herlevsen, Michael A. Harding, (unknown), Christopher A. Moskaluk, Henry F. Frierson, Dan Theodorescu	69
10	The Role of Vascular Endothelial Growth Factor in the Tissue Specific in Vivo Growth of Prostate Cancer Cells 2001 ·Growth Factors ·Tracey L. Krupski, Michael A. Harding, Michael E. Herce, (unknown), Mark H. Stoler, Dan Theodorescu	21
11	Cell density mediated pericellular hypoxia leads to induction of HIF-1α via nitric oxide and Ras/MAP kinase mediated signaling pathways 2001 ·Oncogene ·Essam A. Sheta, (unknown), John J Gildea, Michael A. Harding, Dan Theodorescu	122
12	Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer 2000 ·Genes Chromosomes and Cancer ·John J Gildea, Wendy L. Golden, Michael A. Harding, Dan Theodorescu	70
13	The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines 2000 ·Clinical & Experimental Metastasis ·M. Jabed Seraj, Michael A. Harding, John J Gildea, Danny R. Welch, Dan Theodorescu	112
14	Prostate tumor progression and prognosis 2000 ·Urologic Oncology Seminars and Original Investigations ·Michael A. Harding, Dan Theodorescu	16
15	Transmembrane Motility Assay of Transiently Transfected Cells by Fluorescent Cell Counting and Luciferase Measurement 2000 ·BioTechniques ·John J Gildea, Michael A. Harding, (unknown), Dan Theodorescu	25
16	Prognostic Markers in Localized Prostate Cancer: From Microscopes to Molecules 1998 ·Cancer and Metastasis Reviews ·Michael A. Harding, Dan Theodorescu	13
17	Autosomal-dominant polycystic kidney disease in the rat 1993 ·Kidney International ·Benjamin D. Cowley, Seshagirirao Gudapaty, (unknown), (unknown), Michael A. Harding, James P. Calvet, Vincent H. Gattone	202
18	Localization of overexpressed c-myc mRNA in polycystic kidneys of the cpk mouse 1992 ·Kidney International ·Michael A. Harding, Vincent H. Gattone, Jared J. Grantham, James P. Calvet	55
19	The SGP-2 gene is developmentally regulated in the mouse kidney and abnormally expressed in collecting duct cysts in polycystic kidney disease 1991 ·Developmental Biology ·Michael A. Harding, L Chadwick, Vincent H. Gattone, James P. Calvet	89
20	The Heat Shock Response in HeLa Cells is Accompanied by Elevated Expression of the c- fos Proto-Oncogene 1987 ·Molecular and Cellular Biology ·Glen K. Andrews, Michael A. Harding, James P. Calvet, Eileen D. Adamson	140

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact